Sintx technologies chief strategy officer buys $7,160 in stock

In a recent stock transaction reported on April 22, 2025, Gregg R. Honigblum, the Chief Strategy Officer and Director of Sintx Technologies, Inc. (NASDAQ:SINT), purchased 4,000 shares of common stock. The timing is notable as the stock has fallen nearly 69% over the past year, according to InvestingPro data. The shares were acquired at a price of $1.79 each, amounting to a total investment of $7,160. Following this transaction, Honigblum holds a total of 14,000 shares in the company. This purchase represents a direct ownership interest in the company. The transaction was executed in Salt Lake City, where Sintx Technologies is based. While the company maintains a moderate debt level and strong liquidity with a current ratio of 2.41, InvestingPro analysis indicates the company is quickly burning through cash. Discover more insights about insider trading patterns and 10 additional ProTips with an InvestingPro subscription.

In other recent news, SINTX Technologies has announced a significant reorganization of its Board of Directors, with Eric Olson, the current President and CEO, appointed as the new Chairman. This change follows the retirement of Dr. B. Sonny Bal as Chairman, although he remains on the board to support the company’s strategic goals. The company has also expanded its board with five new directors, each bringing extensive experience in the medical device industry, which aligns with SINTX’s focus on growth in this sector. Additionally, SINTX has completed a $5 million private placement of shares and warrants, with the capital earmarked for working capital purposes. H.C. Wainwright & Co. acted as the exclusive placement agent for this transaction. In other developments, a study conducted by the SRM Institute of Science and Technology highlighted the benefits of SINTX’s silicon nitride material in spinal surgery, noting its superior performance compared to traditional materials. This study underscores the potential for silicon nitride to enhance patient outcomes in spinal fusion procedures. SINTX is actively pursuing strategic partnerships to promote the adoption of its silicon nitride-based medical devices, with the global spinal fusion market presenting significant opportunities.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.